NCT00255346 2025-12-30Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)M.D. Anderson Cancer CenterPhase 2 Completed68 enrolled 13 charts
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT01643603 2020-12-17Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic MalignanciesBarbara Ann Karmanos Cancer InstitutePhase 1 Terminated5 enrolled
NCT02923986 2020-05-28Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDSBio-Path Holdings, Inc.Phase 1/2 Withdrawn
NCT00892190 2016-02-10Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic SyndromeUniversity of PittsburghPhase 1 Completed9 enrolled